A new guidance document for the publication of company-sponsored medical research, has been published online today by the Annals of Internal Medicine [1]. Termed Good Publication Practice 3 (GPP3) the full article describing the guidelines can be accessed at the URL provided below. GPP3 is an update of the original Good Publication Practice (GPP) guidelines, which were originally published in 2003 and updated for the first time in 2009 [2].
In support of GPP3, the International Society for Medical Publication Professionals has also set up a page dedicated to the guidelines. The new guideline includes sections on data sharing, studies that should be published and plagiarism that were not adequately covered in earlier versions. It also expands on the criteria for authorship and author payment/reimbursement and issues related to credibility, integrity, and ethical standards in medical publications, as well as providing additional information on the role of medical writers. In summary, the key principles of GPP3 include:
Transparency and Integrity: It emphasises the importance of disclosing financial and non-financial conflicts of interest, ensuring that company-sponsored research is clearly identified as such, and providing proper attribution for all contributors, including medical writers.
Authorship Criteria: GPP3 follows the International Committee of Medical Journal Editors (ICMJE) guidelines for authorship. All authors must meet specific criteria, including significant contributions to the study, drafting or critically revising the manuscript, and approving the final version.
Accurate and Balanced Reporting: Research findings, whether positive or negative, should be reported accurately and without bias. This includes publishing all relevant data and making results available to the public in a timely manner, even if the outcomes are not favorable to the sponsor.
Ethical Considerations: GPP3 stresses the ethical obligation to ensure patient confidentiality, to avoid plagiarism, and to not engage in ghostwriting. All roles, including those of sponsors, should be clearly defined and disclosed.
Timely and Accessible Communication: It encourages prompt dissemination of research results in a way that is accessible to healthcare professionals, patients, and the public. This includes using peer-reviewed journals and ensuring that research is freely available where possible.
Overall, GPP3 promotes ethical practices to ensure that company-sponsored medical research is communicated transparently and credibly, maintaining public trust in the scientific process.
References
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Searching the literature can take various forms, ranging from a quick scan of recent publications
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
Did you miss our Insider's Insight into understanding the complex world of bibliometrics [1]?
We recently encouraged writers (of all kinds) in our recent Insider’s Insight to experiment with large language.
Scientific knowledge should be accessible to all and if you are those communicating science
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
Since 2013 we have been sharing our understanding on key issues with friends and clients via our Insider’s Insights.
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
Finding the best vehicle in which to publish your research findings is a perennial challenge.
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
I have never been great at conferences. People don’t believe me but I am painfully shy and far too worried about what.
We all need heroes - people who can champion our cause - helping the world to understand our rationale
Our team are exploring different and novel ways for young people to enter the pharmaceutical industry.
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
In the past, Halloween has meant the end of the crop and the start of the dark, cold winter.
I am continually reminded that I must work toward better relationships with my sons than the one I had with my dad.
Get our latest news and publications
Sign up to our news letterSocial
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
